Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 81 to 90 of 315 total matches.

Drugs for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021  (Issue 1620)
, including suppression of T-cell activation and induction and activation of suppressor T cells. Glatiramer ...
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Med Lett Drugs Ther. 2021 Mar 22;63(1620):42-8 |  Show IntroductionHide Introduction

An EUA for Sotrovimab for Treatment of COVID-19

   
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021  (Issue 1627)
appears to retain activity against the B.1.1.7 (Alpha; UK), B.1.351 (Beta; South Africa), P.1 (Gamma ...
The investigational monoclonal antibody sotrovimab (VIR-7831; GSK/Vir Biotechnology) has been granted an FDA Emergency Use Authorization (EUA) for treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease, including hospitalization and death.1 Two other monoclonal antibody regimens are authorized for the same indication: casirivimab (REGN10933) and imdevimab (REGN10987) administered together, and bamlanivimab (LY-CoV555) and etesevimab (LYCoV016) administered together. The FDA revoked its EUA...
Med Lett Drugs Ther. 2021 Jun 28;63(1627):97-8 |  Show IntroductionHide Introduction

Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
and its activation fragment C3b, mitigating the downstream effects of complement activation.3 Key ...
The FDA has approved the complement C3 inhibitor pegcetacoplan (Syfovre – Apellis) for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Given as a series of monthly or every-other-month (EOM) intravitreal injections, it is the first drug to become available for use in patients with atrophic dry AMD. Subcutaneous pegcetacoplan was approved earlier as Empaveli for treatment of paroxysmal nocturnal hemoglobinuria.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):49-50   doi:10.58347/tml.2023.1673a |  Show IntroductionHide Introduction

COVID-19 Updates

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022  (Issue 1642)
-COV) and bamlanivimab plus etesevimab are not active against the Omicron variant of SARS-CoV-2 ...
On January 3, the FDA amended its Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) to incorporate the following changes. The anti-SARS-CoV-2 antibody combinations casirivimab plus imdevimab (REGEN-COV) and bamlanivimab plus etesevimab are not active against the Omicron variant of SARS-CoV-2.
Med Lett Drugs Ther. 2022 Jan 24;64(1642):16 |  Show IntroductionHide Introduction

Prademagene Zamikeracel (Zevaskyn) for Recessive Dystrophic Epidermolysis Bullosa (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
, resulting in low levels or an absence of active type VII collagen. Patients experience severe ...
Prademagene zamikeracel (Zevaskyn – Abeona Therapeutics), an autologous cell sheet-based gene therapy, has been approved by the FDA for treatment of wounds in patients with recessive dystrophic epidermolysis bullosa. It is the first autologous cell sheet-based gene therapy to be approved in the US for this indication. Beremagene geperpavek gel (Vyjuvek), a herpes simplex virus type 1 vector-based gene therapy, is approved for once-weekly use in patients ≥6 months old with recessive dystrophic epidermolysis bullosa.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):e124-5   doi:10.58347/tml.2025.1733l |  Show IntroductionHide Introduction

Sodium Sulfate-Based Tablets (Sutab) for Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
should be used in patients with severe active ulcerative colitis. Table 1. Sutab Clinical Trial Results ...
The FDA has approved an oral tablet formulation of sodium sulfate, magnesium sulfate, and potassium chloride (Sutab – Braintree) for colon cleansing prior to colonoscopy in adults. A sodium sulfate-based oral solution (Suprep) has been available in the US since 2010. Sutab is the second tablet formulation to be approved for bowel cleansing prior to colonoscopy; a sodium phosphate-based tablet (OsmoPrep) was approved earlier.
Med Lett Drugs Ther. 2021 Mar 8;63(1619):33-6 |  Show IntroductionHide Introduction

A New Indication for Esketamine Nasal Spray (Spravato)

   
The Medical Letter on Drugs and Therapeutics • Sep 21, 2020  (Issue 1607)
and active suicidal ideation with intent. In both trials, addition of esketamine 84 mg twice weekly for 4 ...
Esketamine (Spravato – Janssen), an intranasal N-methyl-D-aspartate (NMDA) receptor antagonist that was previously approved by the FDA for treatmentresistant depression,1 has now been approved for treatment of depressive symptoms in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior. Esketamine is the S-enantiomer of the anesthetic ketamine (Ketalar, and generics). It is the first drug to be approved for this indication. Most clinical trials of antidepressants have excluded patients with acute suicidal ideation.
Med Lett Drugs Ther. 2020 Sep 21;62(1607):151 |  Show IntroductionHide Introduction

Apoaequorin (Prevagen) to Improve Memory

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021  (Issue 1636)
is the active ingredient in the over-the-counter dietary supplement Prevagen (Quincy Bioscience), which ...
A synthetic form of the protein apoaequorin is the active ingredient in the over-the-counter dietary supplement Prevagen (Quincy Bioscience), which is heavily marketed to improve memory.
Med Lett Drugs Ther. 2021 Nov 1;63(1636):175-6 |  Show IntroductionHide Introduction

In Brief: Olaparib (Lynparza) for High-Risk Early Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
of single-strand breaks. PARP inhibition leads to double-strand DNA breaks that activate homologous ...
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza – AstraZeneca) has been approved by the FDA for adjuvant treatment of adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative, high-risk early breast cancer who received prior neoadjuvant or adjuvant chemotherapy. The drug was previously approved for treatment of adults with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who received chemotherapy in the neoadjuvant, adjuvant, or metastatic...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e77-8   doi:10.58347/tml.2023.1674j |  Show IntroductionHide Introduction

In Brief: A New Prostate Cancer Indication for Olaparib (Lynparza) (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
of single-strand breaks. PARP inhibition leads to double-strand DNA breaks that activate homologous ...
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza – AstraZeneca) has now been approved by the FDA for use in combination with abiraterone (Zytiga, and others) and either prednisone or prednisolone for treatment of adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib was previously approved by the FDA for treatment of adults with deleterious or suspected deleterious germline or somatic homologous recombinant repair (HRR) genemutated mCRPC who progressed on prior treatment with...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e106-7   doi:10.58347/tml.2023.1679g |  Show IntroductionHide Introduction